Central Bank & Trust Co. Decreases Stake in McKesson Corporation $MCK
by Jessica Moore · The Cerbat GemCentral Bank & Trust Co. lowered its position in shares of McKesson Corporation (NYSE:MCK – Free Report) by 1.5% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 1,983 shares of the company’s stock after selling 31 shares during the quarter. Central Bank & Trust Co.’s holdings in McKesson were worth $1,453,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Oppenheimer Asset Management Inc. grew its holdings in shares of McKesson by 54.0% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,541 shares of the company’s stock worth $3,056,000 after purchasing an additional 1,592 shares during the period. Dynamic Advisor Solutions LLC lifted its position in McKesson by 16.6% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 778 shares of the company’s stock worth $524,000 after acquiring an additional 111 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its position in McKesson by 18.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 23,033 shares of the company’s stock worth $15,501,000 after acquiring an additional 3,659 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in McKesson by 4.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 183,258 shares of the company’s stock worth $123,332,000 after acquiring an additional 7,556 shares in the last quarter. Finally, Acadian Asset Management LLC lifted its position in McKesson by 22.0% during the 1st quarter. Acadian Asset Management LLC now owns 378,926 shares of the company’s stock worth $254,979,000 after acquiring an additional 68,294 shares in the last quarter. Hedge funds and other institutional investors own 85.07% of the company’s stock.
McKesson Stock Down 1.3%
Shares of McKesson stock opened at $702.38 on Tuesday. The firm has a market cap of $87.36 billion, a price-to-earnings ratio of 28.01, a price-to-earnings-growth ratio of 1.41 and a beta of 0.51. The business has a fifty day simple moving average of $697.15 and a 200-day simple moving average of $695.41. McKesson Corporation has a fifty-two week low of $464.42 and a fifty-two week high of $737.89.
McKesson (NYSE:MCK – Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported $8.26 EPS for the quarter, missing the consensus estimate of $8.33 by ($0.07). McKesson had a net margin of 0.84% and a negative return on equity of 196.66%. The company had revenue of $97.83 billion for the quarter, compared to analysts’ expectations of $95.93 billion. During the same period in the prior year, the company earned $7.88 earnings per share. The company’s revenue for the quarter was up 23.4% on a year-over-year basis. Analysts anticipate that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.
McKesson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Tuesday, September 2nd will be issued a dividend of $0.82 per share. This is a positive change from McKesson’s previous quarterly dividend of $0.71. This represents a $3.28 annualized dividend and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, September 2nd. McKesson’s dividend payout ratio (DPR) is currently 13.08%.
Analyst Ratings Changes
Several research firms recently commented on MCK. Wells Fargo & Company boosted their price target on McKesson from $766.00 to $772.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 13th. Wall Street Zen lowered McKesson from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 13th. Cowen reissued a “buy” rating on shares of McKesson in a research report on Thursday, August 7th. Morgan Stanley reissued an “overweight” rating and set a $810.00 price target (up from $770.00) on shares of McKesson in a research report on Wednesday, July 16th. Finally, Evercore ISI upped their target price on McKesson from $760.00 to $800.00 and gave the company an “outperform” rating in a research report on Wednesday, July 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $725.10.
Read Our Latest Stock Report on MCK
Insider Activity
In related news, CEO Brian S. Tyler sold 11,930 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $705.63, for a total value of $8,418,165.90. Following the completion of the sale, the chief executive officer directly owned 4,012 shares of the company’s stock, valued at approximately $2,830,987.56. This represents a 74.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $663.67, for a total value of $218,347.43. Following the completion of the sale, the chief accounting officer directly owned 657 shares of the company’s stock, valued at approximately $436,031.19. This represents a 33.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 43,560 shares of company stock valued at $30,438,602. Company insiders own 0.08% of the company’s stock.
McKesson Profile
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
See Also
- Five stocks we like better than McKesson
- There Are Different Types of Stock To Invest In
- Reddit Hits Record Highs: Why Wall Street Is Taking Notice
- Best Energy Stocks – Energy Stocks to Buy Now
- After a Strong Wall Street Debut, Klarna’s Real Work Begins
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Dividend Growers That Fly Under the Radar
Want to see what other hedge funds are holding MCK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for McKesson Corporation (NYSE:MCK – Free Report).